Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes

References

• Augustijns P, Mols R. HPLC with programmed wavelength fluorescence detection for the simultaneous determination of marker compounds of integrity and P-gp functionality in the Caco-2 intestinal absorption model. Journal of Pharmaceutical and Biomedical Analysis 2004; 34(5)971–978
   PubMed Web of Science ®Google Scholar
• Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15(6)755–772
   PubMed Web of Science ®Google Scholar
• Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998; 21(10)1659–1663
   PubMed Web of Science ®Google Scholar
• Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. American Journal of Medicine 1997; 102(1)99–110
   PubMed Web of Science ®Google Scholar
• Fujita T, Urban TJ, Leabman MK, Fujita K, Giacomini KM. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. Journal of Pharmaceutical Science 2006; 95(1)25–36
   PubMed Web of Science ®Google Scholar
• Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Roland Wolf C, Friedberg T. Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochemical Pharmacology 2002; 64(11)1569–1578
   PubMed Web of Science ®Google Scholar
• Grundemann D, Babin-Ebell J, Martel F, Ording N, Schmidt A, Schomig E. Primary structure and functional expression of the apical organic cation transporter from kidney epithelial LLC-PK1 cells. Journal of Biological Chemistry 1997; 272(16)10408–10413
   PubMed Web of Science ®Google Scholar
• Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. British Journal of Pharmacology 2002; 136(6)829–836
   PubMed Web of Science ®Google Scholar
• Hundal RS, Inzucchi SE. Metformin: New understandings, new uses. Drugs 2003; 63(18)1879–1894
   PubMed Web of Science ®Google Scholar
• Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49(12)2063–2069
   PubMed Web of Science ®Google Scholar
• Kang HJ, Lee SS, Lee CH, Shim JC, Shin HJ, Liu KH, Yoo MA, Shin JG. Neurotoxic pyridinium metabolites of haloperidol are substrates of human organic cation transporters. Drug Metabolism and Disposition 2006; 34(7)1145–1151
   PubMed Web of Science ®Google Scholar
• Kang HJ, Song IS, Shin HJ, Kim WY, Lee CH, Shim JC, Zhou HH, Lee SS, Shin JG. Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metabolism and Disposition 2007; 35(4)667–675
   PubMed Web of Science ®Google Scholar
• Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metabolism and Pharmacokinetics 2005a; 20(5)379–386
   PubMedGoogle Scholar
• Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharmaceutical Research 2005b; 22(2)255–259
   PubMed Web of Science ®Google Scholar
• Klepser TB, Kelly MW. Metformin hydrochloride: An antihyperglycemic agent. American Journal of Health-System Pharmacy 1997; 54(8)893–903
   PubMed Web of Science ®Google Scholar
• Kwong SC, Brubacher J. Phenformin and lactic acidosis: A case report and review. Journal of Emergency Medicine 1998; 16(6)881–886
   PubMedGoogle Scholar
• Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics 2003; 13(9)581–584
   PubMedGoogle Scholar
• Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Clark AG, Herskowitz I, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002; 12(5)395–405
   PubMedGoogle Scholar
• Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clinical Pharmacology and Therapeutics 2006; 79(5)427–439
   PubMed Web of Science ®Google Scholar
• Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, Fukatsu A, Ogawa O, Inui K. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. Journal of American Society in Nephrology 2002; 13(4)866–874
   PubMed Web of Science ®Google Scholar
• Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP, Sheardown SA, Yue L, Burchard EG, Brett CM, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clinical Pharmacology and Therapeutics 2008; 83(2)273–280
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, Ianculescu AG, Yue L, Lo JC, Burchard EG, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. Journal of Clinical Investigation 2007; 117(5)1422–1431
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, Conti F. Disposition of metformin (N,N-dimethylbiguanide) in man. Clinical Pharmacology and Therapeutics 1978; 24(6)683–693
   PubMed Web of Science ®Google Scholar
• Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: Mechanism of action and tolerability. Pharmacological Research 1994; 30(3)187–228
   PubMed Web of Science ®Google Scholar
• Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. British Journal of Clinical Pharmacology 1987; 23(5)545–551
   PubMed Web of Science ®Google Scholar
• Song IS, Han YH, Chung SJ, Shim CK. Contribution of ion-pair complexation with bile salts to the transport of organic cations across LLC-PK1 cell monolayers. Pharmaceutical Research 2003; 20(4)597–604
   PubMed Web of Science ®Google Scholar
• Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. British Journal of Clinical Pharmacology 1981; 12(2)235–246
   PubMed Web of Science ®Google Scholar
• Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. Journal of Pharmacology and Experimental Therapeutics 2002; 302(2)510–515
   PubMed Web of Science ®Google Scholar
• Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Molecular Pharmacology 2003; 63(4)844–848
   PubMed Web of Science ®Google Scholar
• Wang Q, Strab R, Kardos P, Ferguson C, Li J, Owen A, Hidalgo IJ. Application and limitation of inhibitors in drug-transporter interactions studies. International Journal of Pharmaceutics 2007, doi:10.1016/j.ijpharm.2007.12.024
   Web of Science ®Google Scholar
• Yin OQ, Tomlinson B, Chow MS. Variability in renal clearance of substrates for renal transporters in Chinese subjects. Journal of Clinical Pharmacology 2006; 46(2)157–163
   PubMed Web of Science ®Google Scholar